Novavax
| Company type | Public |
|---|---|
| Nasdaq: NVAX | |
| ISIN | US6700024010 |
| Industry | Biotechnology |
| Founded | 1987 |
| Headquarters | , United States |
Area served | Worldwide |
Key people | John C. Jacobs (CEO) James P. Kelly (CFO) |
| Products | Vaccines |
| Revenue | US$682 million (2024) |
| -US$248 million (2024) | |
| -US$187 million (2024) | |
| Total assets | US$1.560 billion (2024) |
| Total equity | -US$623 million (2024) |
Number of employees | 952 (2025) |
| Website | www |
| Footnotes / references | |
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.